Ken Griffin Protalix Bio Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$1.1 - $1.32 $6,050 - $7,260	-5,500 Reduced 54.46%	4,600 $5,000
Q1 2024 May 15, 2024	SELL	$1.22 - $1.82 $16,958 - $25,298	-13,900 Reduced 57.92%	10,100 $12,000
Q4 2023 Feb 14, 2024	SELL	$1.34 - $1.85 $22,512 - $31,080	-16,800 Reduced 41.18%	24,000 $42,000
Q3 2023 Nov 14, 2023	BUY	$1.49 - $2.02 $9,387 - $12,726	6,300 Added 18.26%	40,800 $67,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $20,400 - $34,272	10,200 Added 41.98%	34,500 $69,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.16 $9,590 - $15,120	7,000 Added 40.46%	24,300 $51,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $1.37 $17,300 - $23,701	17,300 New	17,300 $23,000

5.83M

103K

4.6K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $58.7M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.